Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Bladder diseases encompass conditions like urinary blockages, interstitial cystitis, overactive bladder syndrome, cancer, and infections.
• The bladder's anatomy prevents hazardous material entry into circulation.
• Pathogenesis of bladder cancer is assessed by tumor invasion extent, classified as Muscle-Invasive (MBIC) and Non-Muscle Invasive Bladder Cancer (NMIBC).

Purpose of the Study:

• To review novel intravesical drug delivery systems and therapies for bladder disorders.
• To highlight advancements in intravesical chemotherapy, immunotherapy, and drug formulations.
• To discuss emerging intravesical devices and therapeutic modalities.

Main Methods:

• Review of current literature on Intravesical Drug Delivery (IDD) for bladder conditions.
• Analysis of various intravesical agents including chemotherapy, immunotherapy, and novel formulations.
• Examination of advanced drug delivery systems like nanocarriers, hydrogels, and dendrimers.
• Inclusion of intravesical devices and combination therapies.

Main Results:

• Intravesical administration of immunotherapy or chemotherapy reduces bladder cancer recurrence and progression.
• Novel intravesical formulations of gemcitabine, Doxorubicin (DOX), and Mitomycin C (MMC) are effective.
• Various advanced systems including recombinant BCG, gene therapy, Antibody-Drug Conjugates (ADCs), nanocarriers, and hydrogels are utilized.
• Devices like Gem-RIS, hyperthermic intravesical chemotherapy, and photodynamic therapy are employed.

Conclusions:

• Intravesical Drug Delivery (IDD) is a promising approach for managing diverse bladder diseases.
• Advancements in drug formulations and delivery systems enhance treatment efficacy and patient outcomes.
• Combination therapies and novel devices offer expanded therapeutic options for bladder disorders.